Backing Sephience: A Long Trade on PTC Therapeutics Into 2026
PTC Therapeutics is transitioning from royalty receipts to product-led growth centered on Sephience (PKU). With a market cap near $5.7B, strong free cash flow generation and an undemanding EV/EBITDA multiple, PTCT offers a structured long opportunity: entry $70.60, target $95.00, stop $58.00, trade horizon 180 trading days.